IL-15 Enhanced NK Cell Therapy for Solid Tumors
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-70
SponsorGenovn Therapeutics (Suzhou) Co., Ltd.
About this trial
A single-arm, Phase 1 study evaluating safety, tolerability, and preliminary efficacy of IL-15 enhanced engineered NK cells in patients with refractory relapsed or metastatic solid tumors.
Eligibility criteria
Qualifiers
Age 18-70 years;
ECOG 0-1;
histopathologically confirmed metastatic or recurrent solid tumors (breast, liver, lung, etc.);
failed prior standard therapy;
Disqualifiers
Pregnancy/lactation;
other malignancy within 5 years (except cured localized tumors);
active autoimmune disease or immunodeficiency;
uncontrolled cardiovascular disease or infection;
Trial design
Treatments tested in this trial
- IL-15 enhanced engineered NK cells
- IL-15 Enhanced Engineered NK Cells
Treatment groups
12 Participants
are divided into 1 treatment groupLocations
1Xinqiao Hospital Chongqing China
Sponsors and collaborators
Genovn Therapeutics (Suzhou) Co., Ltd.
Lead sponsor
Source ClinicalTrials.gov